| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 09/14/2000 | WO2000030668A8 Use of parvovirus capsid particles in the inhibition of cell proliferation and migration |
| 09/14/2000 | WO2000030425A3 Method of using pon-1 to decrease atheroma formation |
| 09/14/2000 | WO2000027883B1 A method of treating tumors using fas-induced apoptosis |
| 09/14/2000 | WO2000026395A3 Bovine cells expressing adenovirus essential functions for propagation of recombinant adenoviral vectors |
| 09/14/2000 | WO2000024913A3 Mn gene and protein |
| 09/14/2000 | WO2000023599A3 Human proteins involved in endoplasmic reticulum protein degradation |
| 09/14/2000 | DE19911684A1 Human nucleic acid sequences from endothelial cells useful for treatment of angiogenic disease, including psoriasis, arthritis and diabetic retinopathy, etc |
| 09/14/2000 | CA2833396A1 Treatment of alpha-galactosidase a deficiency |
| 09/14/2000 | CA2367334A1 Compositions and methods for the treatment of tumors |
| 09/14/2000 | CA2366147A1 Casb618 polynucleotides and polypeptides and their use |
| 09/14/2000 | CA2366124A1 Hermansky pudlak syndrome protein-interacting proteins and methods of use thereof |
| 09/14/2000 | CA2366087A1 Sialic acid-binding ig-like lectin (siglec) gene; ob-binding protein like (ob-bpl) |
| 09/14/2000 | CA2366078A1 Adipose-derived stem cells and lattices |
| 09/14/2000 | CA2366063A1 Translation regulation system and methods for use thereof |
| 09/14/2000 | CA2365923A1 Medical preparations for the treatment of alpha-galactosidase a deficiency |
| 09/14/2000 | CA2365813A1 Stable recombinant influenza viruses free of helper viruses |
| 09/14/2000 | CA2363255A1 Oligonucleotides containing an antisense sequence stabilised by a secondary structure and pharmaceutical compositions containing same |
| 09/14/2000 | CA2362885A1 Human kallikrein-like genes |
| 09/14/2000 | CA2362422A1 Polynucleotides and proteins encoded thereby |
| 09/14/2000 | CA2362370A1 Use of casb616 polypeptides and polynucleotides for cancer treatment |
| 09/14/2000 | CA2361849A1 Promotion or inhibition of angiogenesis and cardiovascularization |
| 09/14/2000 | CA2361370A1 Prevention and treatment of viral infections |
| 09/13/2000 | EP1035210A2 SIVagm-derived lentiviral vectors, processes for their preparation and their application in the gene transfer in mammalian cells |
| 09/13/2000 | EP1035209A1 Stable recombinant influenza viruses free of helper viruses |
| 09/13/2000 | EP1035208A1 VARIANT loxP SEQUENCES AND APPLICATION OF THE SAME |
| 09/13/2000 | EP1034785A2 Hepatitis C virus diagnostics and vaccines |
| 09/13/2000 | EP1034301A1 Inhibition of an fgf-binding protein using ribozymes |
| 09/13/2000 | EP1034295A1 ribA |
| 09/13/2000 | EP1034292A2 Cell-specific retroviral vectors with antibody domains and method for the production thereof for selective gene transfer |
| 09/13/2000 | EP1034291A2 Pseudo-type retroviral vectors with modifiable surface capsid proteins |
| 09/13/2000 | EP1034288A1 Methods of isolating and using cd7+cd34-lin-hematopoietic cells |
| 09/13/2000 | EP1034273A1 Histamine and serotonin binding molecules |
| 09/13/2000 | EP1034270A1 Compositions and methods of use of het |
| 09/13/2000 | EP1034267A1 Compositions and methods for inducing gene expression |
| 09/13/2000 | EP1034266A1 Method for preparing adenovirus vectors, vectors so prepared, and uses thereof |
| 09/13/2000 | EP1034264A1 Splice variants for human 5-ht 4? serotonin receptor and their applications, in particular for screening |
| 09/13/2000 | EP1034263A1 The nip3 family of proteins |
| 09/13/2000 | EP1034185A2 Pharmaceutical compositions containing the long pentraxin ptx3 |
| 09/13/2000 | EP1034004A1 Recombinant mycoplasma hyopneumoniae vaccine |
| 09/13/2000 | EP1033992A1 Rnase l activators and antisense oligonucleotides effective to treat rsv infections |
| 09/13/2000 | EP0957902A4 System for genetically treating cardiac conduction disturbances |
| 09/13/2000 | EP0938557B1 Methods and compositions for inhibiting inflammation and angiogenesis comprising a mammalian cd97 alpha subunit |
| 09/13/2000 | EP0586570B1 Backbone modified oligonucleotide analogues |
| 09/13/2000 | CN1265921A Erythropoiesis for treating anemia of family and raised animals |
| 09/12/2000 | US6117978 Protein having at least 63% identity to human protein having defined amino acid sequence; for diagnosis and therapy of alzheimer's disease; drug screening |
| 09/12/2000 | US6117858 For specific delivery of biologically active substances to achieve lower doses and for improved efficacy with drugs such as oligonucleotides and polynucleotides with problems in achieving therapeutic concentrations at targeted organs |
| 09/12/2000 | US6117848 Antisense oligonucleotide inhibition of ras |
| 09/12/2000 | US6117681 Pseudotyped retroviral particles |
| 09/12/2000 | US6117680 Compositions and methods for regulation of transcription |
| 09/12/2000 | US6117633 Detecting nucleotide sequences coding antitumor protein; hyridizing sequences of normal and cancer cells, probing libraries with sequences, isolating and fragmenting clones, insertion in vectors, isolate specific nucleotide sequences |
| 09/08/2000 | WO2000052462A1 Heart abnormalities in vascular endothelial growth factor b (vegf-b) deficient animals and methods relating to these heart abnormalities |
| 09/08/2000 | WO2000052210A2 Methods for targeting rna molecules |
| 09/08/2000 | WO2000052205A2 cDNA FOR HUMAN METHYLENETETRAHYDROFOLATE REDUCTASE |
| 09/08/2000 | WO2000052187A2 Enhanced system for construction of adenovirus vectors |
| 09/08/2000 | WO2000052186A1 Means and methods for fibroblast-like or macrophage-like cell transduction |
| 09/08/2000 | WO2000052185A1 Application of dna vectors for the treatment of viral infection |
| 09/08/2000 | WO2000052184A1 Anti-neoplastic compositions and uses thereof |
| 09/08/2000 | WO2000052165A2 Compositions and methods for breast cancer therapy and diagnosis |
| 09/08/2000 | WO2000052159A1 Methods and reagents for inhibiting proliferation of smooth muscle cells |
| 09/08/2000 | WO2000052158A1 Methods and reagents for inhibiting angiogenesis |
| 09/08/2000 | WO2000052156A1 Regulatory constructs comprising intron 3 of prostate specific membrane antigen gene |
| 09/08/2000 | WO2000052149A1 Introducing a biological material into a patient |
| 09/08/2000 | WO2000052136A2 Human glycosylation enzymes |
| 09/08/2000 | WO2000052044A1 Transmembrane serine protease overexpressed in ovarian carcinoma and uses thereof |
| 09/08/2000 | WO2000052028A1 TUMOR NECROSIS FACTOR RECEPTORS 6α and 6$g(b) |
| 09/08/2000 | WO2000052024A1 POLYNUCLEOTIDE AND POLYPEPTIDE SEQUENCES ENCODING HUMAN ORGANIC ANION TRANSPORTER 6(hOATP6) AND SCREENING METHODS THEREOF |
| 09/08/2000 | WO2000051630A2 Methods for improving graft acceptance in a recipient by administration of a cytokine profile altering agent |
| 09/08/2000 | WO2000051432A1 Vaccines and gene therapy compositions and methods of making and using the same |
| 09/08/2000 | WO2000051430A1 Human fas |
| 09/08/2000 | WO2000051424A2 Genetic modification of somatic cells and uses thereof |
| 09/08/2000 | WO2000027414A3 Inhibition of the formation of vascular hyperpermeability |
| 09/08/2000 | WO2000023592B1 Minimal promoters and uses thereof |
| 09/08/2000 | WO2000020026A3 Compositions and methods for inhibiting angiogenesis |
| 09/08/2000 | WO2000019883A3 Compositions and methods of disease diagnosis and therapy |
| 09/08/2000 | WO2000019206A9 Ykl-40 as a marker and prognostic indicator for cancers |
| 09/08/2000 | WO2000015853A9 Recombinant newcastle disease virus rna expression systems and vaccines |
| 09/08/2000 | WO2000013702A3 Use of an angiogenic factor for the treatment of microvascular angiopathies |
| 09/08/2000 | WO2000012702A3 Human genes differentially expressed in colorectal cancer |
| 09/08/2000 | WO2000000604A9 Methods and compositions for modulating spermatogenesis |
| 09/08/2000 | WO1999061068A9 Anti-prostate cancer vaccines, and methods of making, using and evaluating the same |
| 09/08/2000 | WO1999053961A9 Peptides for efficient gene transfer |
| 09/08/2000 | WO1999015650A9 Expression of endogenous genes by non-homologous recombination of a vector construct with cellular dna |
| 09/08/2000 | CA2371846A1 Methods and reagents for inhibiting proliferation of smooth muscle cells |
| 09/08/2000 | CA2364492A1 Regulatory constructs comprising intron 3 of prostate specific membrane antigen gene |
| 09/08/2000 | CA2364463A1 Introducing a biological material into a patient |
| 09/08/2000 | CA2364279A1 Methods for improving graft acceptance in a recipient by administration of a cytokine profile altering agent |
| 09/08/2000 | CA2363488A1 Heart abnormalities in vascular endothelial growth factor b (vegf-b) deficient animals and methods relating to these heart abnormalities |
| 09/08/2000 | CA2363139A1 Methods and reagents for inhibiting angiogenesis |
| 09/08/2000 | CA2363077A1 Methods for targeting rna molecules |
| 09/08/2000 | CA2362995A1 Anti-neoplastic compositions and uses thereof |
| 09/08/2000 | CA2362873A1 Vaccines and gene therapy compositions and methods of making and using the same |
| 09/08/2000 | CA2362825A1 Cdna for human methylenetetrahydrofolate reductase |
| 09/08/2000 | CA2361593A1 Human glycosylation enzymes |
| 09/07/2000 | DE19909770A1 Bakterienghosts als Träger- und Targetingvehikel Bacterial ghosts as carrier and targeting vehicles |
| 09/07/2000 | DE19909769A1 Von SIVagm abgeleitete lentivirale Vektoren, Verfahren zu ihrer Herstellung und ihre Verwendung zur Genübertragung in Säugerzellen Of SIVagm-derived lentiviral vectors, processes for their preparation and their use for gene transfer into mammalian cells |
| 09/07/2000 | DE19907099A1 Novel nucleic acid construct useful in gene therapy comprising an hormone responsive element and transgene in which the hormone responsive element is not functionally linked to the transgene |
| 09/06/2000 | EP1032838A1 125 human secreted proteins |
| 09/06/2000 | EP1032706A1 Reagents and methods useful for detecting diseases of the breast |
| 09/06/2000 | EP1032697A1 High efficiency retroviral vectors that contain none of viral coding sequences |
| 09/06/2000 | EP1032696A1 Vector for tissue-specific replication and gene expression |